Plasma Mitochondrial DNA Clearance by Continuous Venovenous Haemofiltration in Critically Ill Patients

Abstract

Abstract Objective Mitochondrial DNA (mtDNA) reportedly has diagnostic and predictive value in critically ill patients. This study evaluated the diagnostic and predictive value of mtDNA in patients undergoing continuous venovenous haemofiltration (CVVH). Methods We consecutively enrolled 41 patients who were treated with CVVH from September 2018 to December 2019. Prefilter, postfilter, and ultrafiltrate samples were collected before the initiation of CVVH (T0) and 6 and 12 h after CVVH. The total mass removal rate (Mtr), total mass adsorption rate (Mad), plasma clearance (PC), and sieving coefficient (SC) were calculated based on the mass conservation principle. Results The plasma mtDNA concentration in patients at T0 prefilter was higher than that in healthy volunteers [13.77 (12.45–15.86) vs. 1.24 (1.15–1.34) ng/mL, P 0.05 for all). Conclusions Plasma mtDNA in critically ill patients was significantly affected by CVVH. Trial registration: Retrospectively registered on 20 August 2019 at ClinicalTrials.gov (NCT04083482).

Keywords

• Mitochondrial DNA
• Continuous venovenous haemofiltration
• Mass conservation principle
• Intensive care unit
• Continuous renal replacement therapy